Creo Medical Group Statistics

Total Valuation

AIM:CREO has a market cap or net worth of GBP 60.87 million. The enterprise value is 44.57 million.

Market Cap	60.87M
Enterprise Value	44.57M

Important Dates

The next estimated earnings date is Wednesday, May 13, 2026.

Earnings Date	May 13, 2026
Ex-Dividend Date	n/a

Share Statistics

AIM:CREO has 402.47 million shares outstanding. The number of shares has increased by 17.86% in one year.

Current Share Class	402.47M
Shares Outstanding	402.47M
Shares Change (YoY)	+17.86%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	3.58%
Owned by Institutions (%)	86.80%
Float	364.20M

Valuation Ratios

The trailing PE ratio is 68.59.

PE Ratio	68.59
Forward PE	n/a
PS Ratio	13.23
PB Ratio	1.00
P/TBV Ratio	1.01
P/FCF Ratio	8.70
P/OCF Ratio	8.95
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	89.15
EV / Sales	9.69
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	6.37

Financial Position

The company has a current ratio of 5.28, with a Debt / Equity ratio of 0.07.

Current Ratio	5.28
Quick Ratio	4.47
Debt / Equity	0.07
Debt / EBITDA	n/a
Debt / FCF	0.60
Interest Coverage	-57.50

Financial Efficiency

Return on equity (ROE) is 4.80% and return on invested capital (ROIC) is -51.57%.

Return on Equity (ROE)	4.80%
Return on Assets (ROA)	-20.82%
Return on Invested Capital (ROIC)	-51.57%
Return on Capital Employed (ROCE)	-36.62%
Weighted Average Cost of Capital (WACC)	7.24%
Revenue Per Employee	35,659
Profits Per Employee	3,876
Employee Count	129
Asset Turnover	0.07
Inventory Turnover	0.43

Taxes

Income Tax	-700,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +1.65% in the last 52 weeks. The beta is 0.54, so AIM:CREO's price volatility has been lower than the market average.

Beta (5Y)	0.54
52-Week Price Change	+1.65%
50-Day Moving Average	13.34
200-Day Moving Average	12.60
Relative Strength Index (RSI)	48.06
Average Volume (20 Days)	1,021,460

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AIM:CREO had revenue of GBP 4.60 million and earned 500,000 in profits.

Revenue	4.60M
Gross Profit	2.10M
Operating Income	-23.00M
Pretax Income	1.90M
Net Income	500,000
EBITDA	-23.30M
EBIT	-23.00M
Earnings Per Share (EPS)	-0.00

Full Income Statement

Balance Sheet

The company has 20.50 million in cash and 4.20 million in debt, giving a net cash position of 16.30 million or 0.04 per share.

Cash & Cash Equivalents	20.50M
Total Debt	4.20M
Net Cash	16.30M
Net Cash Per Share	0.04
Equity (Book Value)	60.90M
Book Value Per Share	0.15
Working Capital	25.70M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 6.80 million and capital expenditures 200,000, giving a free cash flow of 7.00 million.

Operating Cash Flow	6.80M
Capital Expenditures	200,000
Free Cash Flow	7.00M
FCF Per Share	0.02

Full Cash Flow Statement

Margins

Gross margin is 45.65%, with operating and profit margins of -500.00% and 10.87%.

Gross Margin	45.65%
Operating Margin	-500.00%
Pretax Margin	41.30%
Profit Margin	10.87%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	152.17%

Dividends & Yields

AIM:CREO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-17.86%
Shareholder Yield	-17.86%
Earnings Yield	0.82%
FCF Yield	11.50%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AIM:CREO has an Altman Z-Score of 1.76 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.76
Piotroski F-Score	5